The global genome editing market was worth USD 4.85 billion in 2023. The global market is expected to grow at a CAGR of 14.42% from 2024 to 2029 and be worth USD 10.88 billion by 2029 from USD 5.55 billion in 2024.
Genome editing is used to change the DNA sequence of an organism. To do this, various types of enzymes such as CRISPR/Cas9, TALENs, or ZFNs are used as these can make such changes in the genomes. Genome editing is used to cure genetically inherited diseases, enhance the quality of crops, and provide valuable insights to understand the behind the story of genetic diseases, due to which the adoption of genome editing is growing rapidly. The usage of genome editing is not limited to life sciences but also has a presence in medicinal and agricultural industries. In the coming years, genome editing is predicted to play a significant role in the biotechnological industry.
The usage of genome editing techniques to develop new genetically modified crops is on the rise. Currently, genome editing is being used in genetically modified crops to better their yield, provide the capacity to fight against pests and diseases, and make them capable of handling various environmental conditions. The need for genetically modified crops is growing significantly worldwide owing to the increasing population and rising need for increased food production. In the same ratio, the involvement of genome editing in genetically modified crops is increasing and resulting in market growth.
The global genome editing market is further progressing due to the more significant number of application areas such as therapeutics, mutation and agriculture, and biotechnology. These technologies offer many openings in crop improvement in gene-targeted exchange therapy, which is not yet grasped. For crop improvements, homologous recombination is an effective procedure and is expected to drive the global genomic editing market in the future. Furthermore, the scope of the genomic editing market is rising due to increasing applications and diseases. Genome editing has a substantial range to treat a diversity of cancers, genetically affected cells, and agents of infectious diseases such as parasites, viruses, bacteria, and others.
Furthermore, the growing focus of government and private organizations to invest in research and developments of genome editing, the rising number of applications in therapeutics, agriculture, biotechnology, and mutation fields, and to treat of genetically affected cells and various infections are likely to provide lucrative opportunities for the growth of the global genome editing market over the forecast period.
Technical limitations are another notable factor inhibiting market growth. Factors such as regulatory issues, high costs associated with genome editing technology, poor awareness among people in some countries, and the availability of alternative technologies are anticipated to showcase a negative impact on the growth of the genome editing market. In addition, concerns for animal welfare can rise at all generation phases, and the life duration of genetically engineered animals hinders the global genome editing market.
The COVID-19 pandemic has had a mixed impact on the growth of the global genome editing market. On the positive end, scientists have been using CRISPR technology to develop rapid diagnostic tests for SARS-COV-2. In addition, scientists are looking at CRISPR as a potential therapeutic utilized in targeted enzymatic activity to destroy the coronavirus RNA and prevent virus replication. Technology-based gene-editing systems play a vital role in defense against infection. Due to COVID-19, the demand for gene therapy has grown significantly as it is considered one of the potential treatment options for COVID-19.
On the other hand, the COVID-19 pandemic has resulted in decreased funding for genome editing, closure of laboratories, supply chain disruptions, and delays in clinical trials, which had a negative impact on the growth of the genome editing market. Likewise, the genome editing market has experienced a mixed impact of the COVID-19 pandemic. However, considering the reduced impact of the COVID-19 pandemic and growing habituation toward new normalization by people and companies, the genome editing market is anticipated to showcase a healthy CAGR during the forecast period.
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 to 2029 |
|
Base Year |
2023 |
|
Forecast Period |
2024 to 2029 |
|
Segments Covered |
By Application, Technology, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
|
Key Market Players |
Thermo Fisher Scientific, Merck KGAA, Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies, and Transposagen Biopharmaceuticals |
Based on application, the cell line engineering segment had the major share of the global genome editing market in 2022 and is expected to grow at the highest CAGR during the forecast period. The segment's growth is primarily driven by the increasing demand for stem cell therapies, the rising focus of key market players on stem cell research, and growing funds from private and public sectors. In addition, factors such as the growing need for biopharmaceuticals and increasing usage of drug discovery are anticipated to fuel the segment’s growth rate.
On the other hand, the animal genetic engineering segment is expected to grow at a promising CAGR during the forecast period. This is because the growing usage of genome editing majorly drives the segmental growth to develop new animal models and promote animal health and productivity.
The plant genetic engineering segment is anticipated to register a healthy CAGR in the coming years. The growing need to promote the yield of crops and make them capable of handling the environmental changes in the agricultural industry is primarily driving segmental growth.
Based on technology, the CRISPR segment held a leading share of the global genome editing market in 2022, and the domination of the segment is likely to continue during the forecast period owing to its ability to target multiple sites simultaneously in a single cell using various guide RNAs. The CRISPR technology is easy to use and has higher efficiency than the other available technologies, due to which the adoption of technology is growing faster and resulting in segmental growth. Many researchers and companies in applications such as cell line engineering, animal genetic engineering, and plant genetic engineering have widely used CRISPR.
Based on end-users, the academic and research institutes segment is anticipated to hold a major share of the global genome editing market during the forecast period. Factors such as the increasing number of initiatives from various governments in favor of genome editing and the availability of funding for stem cell therapies and genetic editing research support segmental growth.
The CROs segment is predicted to register a healthy CAGR in the coming years owing to the increasing outsourcing activities by pharmaceutical and biotechnological companies for their research needs.
The global genome editing market was dominated by North America in 2022, with the region accounting for 40% of the overall market share. North America was followed next in line by Europe and Asia-Pacific. The North American genome editing market will likely dominate during the forecast period owing to the growing funding by North American countries for genomic modification. In addition, acceptance of government funding and research grants, GM crop adoption, and development in gene therapy anticipate the growth of the genome editing market in North America.
The European genome editing market is another potential regional market for genome editing worldwide and is estimated to hold a substantial share of the global market during the forecast period. The presence of numerous pharmaceutical and biotechnological companies in Europe, an increasing number of academic and governmental research institutes, and growing investments to conduct R&D in the genome editing field are majorly propelling regional market growth. In addition, the presence of favorable government policies in the European region is aiding the growth of the European market.
The Asia-Pacific genome editing market is expected to increase in the coming years, as evidenced by the region's high CAGR value. Another promising area for the market in Latin America, which is expected to show high growth rates in the coming years. The Asia Pacific has had a steady growth in the market for the past few years due to the upsurge in investments by essential players in the region. The rise in government initiatives to fund start-up companies and new players in the pharmaceutical and biotechnology industries and the increase in drug discovery and development activities are the major factors anticipated to drive the genome editing market growth in the Asia Pacific region during the forecast period.
The MEA genome editing market is expected to grow at a moderate CAGR in the coming years.
Noteworthy companies profiled in this report in the global genome editing market are Thermo Fisher Scientific, Merck KGAA, Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies, and Transposagen Biopharmaceuticals.
By Application
By Technology
By End-users
By Region
Frequently Asked Questions
As per our research report, the global genome editing market size is projected to be USD 9.51 billion by 2028.
Geographically, North American genome editing accounted for the largest share of the global market in 2022.
The global genome editing market is estimated to grow at a CAGR of 14.42% from 2023 to 2028.
Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies are some of the significant players operating in the genome editing market
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region